Boehringer Ingelheim expands development capacities with new technical centre

Boehringer IngelheimThe research driven pharmaceutical company Boehringer Ingelheim is establishing a new 50 million-plus euro pilot plant facility for the production of newly developed active pharmaceutical ingredients. The company announced this investment in its largest research and development site worldwide in Biberach, Germany. With the construction of the new facility, Boehringer Ingelheim is ensuring that the substances from the well-stocked "research pipeline" - in other words, the supply of innovative compounds - are available for clinical studies in sufficient amounts. “In order to continue offering new products in therapeutic areas with significant unmet medical needs, such as diabetes, cancer, hepatitis C, idiopathic pulmonary fibrosis and asthma, we need to invest now”, explained Professor Andreas Barner, Chairman of the Board of Managing Directors, at the ceremony for the laying of the foundation stone in Biberach. The new technical centre is scheduled for completion in early 2014.

In the research and development process for new pharmaceutical products, the required amount of a new active ingredient grows steadily as progress is made. Whilst substance amounts measured in milligrams are sufficient during the early phases of research, the need for toxicological and pharmaceutical tests means that the amounts needed rise significantly to the two- or three-digit kilogram range in later stages. With 15 chemical reactors with volumes of 100 to 300 litres, the new pilot facility in Biberach will have the capacity to provide these substance amounts.

"The pilot facility will make it possible to produce sufficient amounts to provide active ingredients from the global group’s own research and development for later phases," affirmed Dr Wolfgang Baiker, Corporate Senior Vice President for Development. The new technical centre will have a useable area of approximately 2,700 square metres and will host four manufacturing bays including four synthesis laboratories, which will handle the transfer of processes from laboratory to technical scale.

"In the past, the successful research and development activities of Boehringer Ingelheim and the innovative strength that accompanies them have been the basis for our positive economic development. Our in-house research and development will continue to be of the utmost priority in future," stated Prof. Barner. "The construction of the new technical centre in Biberach is a clear sign of that." Last year alone, the pharmaceutical company invested more than 2.5 billion euro in the research and development of new medications.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsibly. Involvement in social projects, caring for employees and their families and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavours.

In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]